Business to Biotech Event

Dr. McGinty did her training in Ireland at the National University followed by radiology residency at the University of Pittsburgh, fellowship in Women's Imaging at Massachusetts General Hospital and an MBA at Columbia University. ​

​

In 2018 she was elected as the first female Chair of the American College of Radiology's Board. Since 2014 she has been on the faculty at Weill Cornell Medicine in New York also serving as Chief Strategy Officer from 2017-2021. She also teaches in the WCM and Cornell School of Business EMBA/MS in Healthcare Leadership. In 2021 she was appointed as Senior Associate Dean for Clinical Affairs. She is a member of the board of NextGen Healthcare (NXGN). Her published work has focused on payment models for imaging. Recently she has focused on the impact of Artificial Intelligence on imaging. In 2015 she was voted Radiology’s Most Effective Educator by the readers of Aunt Minnie. She has more than 16000 followers on Twitter. 

https://www.linkedin.com/in/geraldinemcgintymd/

Sabriya Stukes is the Chief Scientific Officer for IndieBio NY. IndieBio is the world's leading seed-stage life science startup development program with the mission of training scientists to become entrepreneurs to solve the most pressing issues in human and planetary health. Prior to joining IndieBio, she was the operations director for Stellate Therapeutics, a NY based biotech company that focused on the use of microbiome-derived molecules to treat neurodegenerative disorders. Additionally, from 2016-2021, she was the founding Associate Director of the Master's in Translational Medicine (MTM) program at The City College of New York, a brand new type of graduate degree that educates and trains scientists and engineers in the hands-on process of medical technology commercialization and healthcare innovation. A microbiologist, educator and science communicator, her expertise is in working with individuals to identify unmet community needs, design sustainable clinical solutions, think critically about the world around them and craft compelling scientific narratives. She also has worked for over a decade in fostering equitable and inclusive environments in the STEM disciplines and thinks deeply about how we can build sustainable healthcare solutions that work for all and not just some. 

https://www.linkedin.com/in/sabriya-stukes-phd/​

https://indiebio.co/

With 30 years of leadership experience in both technology and pharmaceuticals, Innes Meldrum brings an authentic, charismatic, cross-cultural leadership approach to successfully deliver business growth through highly engaged organizations. ​

▪ Developing and successfully commercializing novel treatments for area’s of significant unmet need ​

▪ Profitably growing a complex, highly regulated business ​

▪ Leading the transformation of commercialization model and supporting technology ​

▪ Building a highly engaged organization with deep talent bench ​

▪ Driving strong revenue growth while increasing profit contribution with and without alliance partners ​

▪ Providing cross-cultural leadership within multi-national organizations across small, mid-size & large Pharma ​

▪ Strategic planning, pipeline optimization & new product commercialization ​

▪ Compliance and Corporate Governance ​

​

Meldrum is currently the President and CEO of Reset Pharma, a New York based Clinical stage, Neuro Biotechnology company focused on developing Psychedelics to treat Mental Health issues associated with life threatening diseases. In this role, Meldrum leads all operational, development and fund-raising activities. ​

Prior to this role, Meldrum was Chief Commercial Officer for Otsuka Pharma North America, taking on this role at the start of the Covid Pandemic. Growing revenue 32% to $2.5B, increasing operating income 68% to $940M and simultaneously improving employee engagement to 84% (~20% above pharma industry norm) while delivering a strategic transformation of the commercialization model. ​

Meldrum served as a key member of the North American Executive team reporting into the Global CEO and was a member of the Otsuka Global Strategic Forum, a member of the Otsuka Canada Board & co-chaired the key Global Clinical Development and Commercialization committees within Otsuka and across alliances. ​

Prior to his CCO role Meldrum served as the US CNS Business Unit head, successfully managing a challenging Alliance relationship to increase investment and consistently exceed all financial targets. ​

Before joining Otsuka in early 2017 Meldrum led Commercial activities at the Addiction focused startup “Orexo” and before this spent 11 years in commercial roles of increasing responsibility with Novartis Pharma here in the US and within the Global Organization based in Switzerland. ​

Before entering Healthcare he spent 10 years leading businesses in the tech. industry leveraging his Electrical and Electronic undergraduate degree from Strathclyde Uni. (Scotland) in 1993. 

https://www.resetpharma.com/​​

https://www.linkedin.com/in/innesmeldrum/

Seema Kumar joined Cure Experience in 2022 as the Chief Executive Officer. Prior to Cure, Ms. Kumar spent nearly 20 years at Johnson & Johnson in senior leadership roles, including most recently as the Global Head, Office of Innovation, Global Health and Scientific Engagement, and served on J&J’s Innovation Strategy, Public health leadership and the COVID-19 vaccine steering committee, where she led the company’s external affairs efforts and public education program on COVID and vaccine literacy. Before her tenure at J&J, Ms. Kumar was the Chief of Staff to Dr. Eric Lander and the Chief Communications Officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research where she played a leadership role in the Human Genome Project. She also has held leadership positions at the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, and Johns Hopkins School of Medicine. Ms. Kumar holds an M.S. in Science Journalism and Communications from the University of Maryland.

https://www.linkedin.com/in/kumarseema/​

https://wewillcure.com

With a successful track record as a serial entrepreneur in the business and science of medicine, Laurence (Laur) Blumberg has three decades of innovating as an operating executive, Board Director, and investor. With his foundational years in healthcare equity research and capital management, he successfully founded and led multiple life-science companies as: CEO, COO, SVP, and President and/or Director of the Board, with strategic oversight of operating, clinical, and business functions. Most recently, Laur was President & CEO of Arch Oncology a privately held clinical-stage immuno-oncology company focused on the CD47 pathway. Laur joined the company to complete a successful $105m Series C and lead clinical development through a definitive clinical readout. Previously, Laur was the business founder of Syntimmune, where he served in a variety of leadership capacities (including founding CEO and President, COO and President, and Director), where he ultimately led the company through to successful acquisition by Alexion, in a precedent-setting all-cash transaction for up to $1.2 billion, $400 million of which was upfront.  Before Syntimmune, Laur was Senior Vice President, Business Development and later Project Management at Kadmon Corporation from company founding until his move to Syntimmune. Earlier in his career and also as a business-founder Laur launched Syntonix Pharmaceuticals in 1998, serving as a Director of the Board through to its Biogen acquisition---another cash deal, valued at $120 million. Notably, the hemophilia pre-clinical drug development programs at Syntonix went on to receive US and EU regulatory approvals as Eloctate and Alprolix, and in excess of $2.0 billion in annual sales under Sanofi. Prior to joining the operating sides of life-sciences, Laur was Managing Member of Blumberg Capital, a life science and healthcare investment partnership in addition to serving as VP, Equity Research as the senior biotechnology and medical device analysis for Alliance Capital. He was also a co‐founder and director of Cambridge Heart, a cardiac medical diagnostic company that went public with Goldman Sachs and Bear Stearns. Laur received a BA from Brandeis University in 1983, magna cum laude, with highest honors in physics, an M.D. from Temple University School of Medicine in 1987, and an Executive MBA from Columbia University School of Business in 1994. He completed an Internship in Surgery at Abington Memorial Hospital and was an Otolaryngology resident at Geisinger Medical Center. More recently from 2013 to 2017, Laur was an Entrepreneur in Residence at Columbia Business School. Laur currently serves as a Lecturer at Weill Cornell Medicine teaching Entrepreneurship in Life Sciences in the Department of Population Health Sciences.

https://www.linkedin.com/in/laurence-blumberg-md-33b870a/​